Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.62 |
| ▸ | HSD17B13 | Q7Z5P4 | 2/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | FABP1 | P07148 | 9/20 | 0.61 |
| ▸ | FABP4 | P15090 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114799 | 0.91 | NR1H4 (0.71) | NR1H4HSD17B13NR1I2CYP1A2CYP3A4 | |
| SCHEMBL2001904 | 0.85 | NR1H4 (0.62) | NR1H4HSD17B13CYP1A2CYP2C9FABP1 | |
| SCHEMBL2113528 | 0.85 | NR1H4 (0.84) | NR1H4NR1I2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2000305 | 0.84 | NR1H4 (0.62) | NR1H4HSD17B13CYP1A2CYP2C9FABP1 | |
| SCHEMBL4950828 | 0.83 | NR1H4 (0.64) | NR1H4NR1I2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1999023 | 0.83 | NR1H4 (0.66) | NR1H4HSD17B13FABP1FABP4 | |
| SCHEMBL2005963 | 0.82 | NR1H4 (0.65) | NR1H4HSD17B13CYP1A2CYP2C9FABP1 | |
| SCHEMBL13335357 | 0.80 | NR1H4 (0.71) | NR1H4HSD17B13FABP1FABP4 | |
| SCHEMBL2002938 | 0.80 | NR1H4 (0.55) | NR1H4HSD17B13FABP1FABP4 | |
| SCHEMBL2006338 | 0.80 | NR1H4 (0.72) | NR1H4HSD17B13CYP1A2CYP2C9FABP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158665-B2 | Farnesoid X receptor agonists | GLAXOSMITHKLINE LLC (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158665-B2 | Farnesoid X receptor agonists | GLAXOSMITHKLINE LLC (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158665-B2 | Farnesoid X receptor agonists | GLAXOSMITHKLINE LLC (US) | 2012-04-17 | — | — | US | disclosed |
| EP-1962838-B1 | FARNESOID X RECEPTOR AGONISTS | GLAXOSMITHKLINE LLC (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100160398-A1 | Farnesoid X Receptor Agonists | GLAXOSMITHKLINE LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160398-A1 | Farnesoid X Receptor Agonists | GLAXOSMITHKLINE LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160398-A1 | Farnesoid X Receptor Agonists | GLAXOSMITHKLINE LLC | 2010-06-24 | — | — | US | disclosed |
| US-7705028-B2 | Farnesoid X receptor agonists | GLAXOSMITHKLINE LLC (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705028-B2 | Farnesoid X receptor agonists | GLAXOSMITHKLINE LLC (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705028-B2 | Farnesoid X receptor agonists | GLAXOSMITHKLINE LLC (US) | 2010-04-27 | — | — | US | disclosed |
| EP-1962838-A2 | FARNESOID X RECEPTOR AGONISTS | Smithkline Beecham Corporation (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20080167356-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167356-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167356-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2007076260-A2 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167356-A1 | FARNESOID X RECEPTOR AGONISTS | NR1H4, NR1H3, NR1H2 | NR1H4 1/4885HSD17B13 156/4885NR1I2 10/4885 |
| US-20100160398-A1 | Farnesoid X Receptor Agonists | NR1H4, NR1H3, NR1H2 | NR1H4 1/4885HSD17B13 156/4885NR1I2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.